COMPANY PROFILE

Deka Biosciences

Explore full profile

Developing life-changing and enabling medicines for patients with cancer and inflammatory diseases

Germantown, United StatesFounded 2019Biotech & Life Sciences

Valuation $100–250M Last recorded · 2023

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Deka Biosciences

Deka BioSciences, Inc. is a biotechnology company focused on developing and delivering transformative medicines for patients suffering from cancer and inflammatory diseases. The company leverages the natural properties of cytokines, specifically IL-10 and IL-4, to enhance their anti-inflammatory functions and target tumor microenvironments effectively. By combining these cytokines, Deka BioSciences aims to suppress inflammatory responses and improve the efficacy of cancer treatments. The company operates in the biopharmaceutical market, serving patients with conditions such as sepsis, psoriasis, and rheumatoid arthritis. Deka BioSciences generates revenue through the development and commercialization of its proprietary medicines, targeting both domestic and global markets. The business model includes research and development, clinical trials, and partnerships with healthcare providers and pharmaceutical companies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2019
Headquarters: Germantown, United States
Employees: 15
Open positions: None listed
Dealroom signal: 60.2/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Dec 2023	$30M	$120M	Undisclosed	↗
SERIES BOther financing	Sep 2023	$20M	$108M	MPM BioImpact · Lumira Ventures · Leaps by Bayer · Viva BioInnovator	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Deka Biosciences website traffic

Latest recorded traffic for Deka Biosciences is 1K monthly website visits, down 33.3% over the last three months.

Latest monthly visits1K 3-month web change-33.3%

Monthly website visitsOct 2022–Jun 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
FIFibroBiologicsDeveloping therapies using fibroblasts, which are a type of cell that is found in connective tissue	Houston, United States	Operational	14	$103M	$253M
OBOcelot BioBiotech & Life Sciences	San Diego, United States	Operational
1T101 TherapeuticsDeveloping the first targeted glucocorticoid with all of the potency of steroids but none of the systemic toxicities	Tel Aviv-Yafo, Israel	Operational
CICianatxInnovative therapies for Diabetic Retinopathy, preventing vision loss and blindness with novel treatments	Annapolis, United States	Operational
APAculys PharmaCommitted to the patient experience including the awareness, screening, diagnosis, treatment of disease and the resolution of surrounding social issues for patients and their families confronted with neurological and psychiatric disease	Fujisawa, Japan	Acquired
BIBiofronteraSpecializing in dermatological products commercializing a portfolio of dermatological drugs specializing on the fields of photodynamic therapy (PDT) and topical antibiotics	Woburn, United States	Operational
EBEucure BiopharmaInnovative immuno-oncology targeted antibodies advancing through clinical trials	Guangzhou, China	Operational
ETElastrin TherapeuticsReversing diseases by targeting damaged elastin fibers	Simpsonville, United States	Operational